RIO Trial
@riotrial.bsky.social
Hello, RIO Trial is also now on Bluesky!
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
April 23, 2025 at 8:07 AM
@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs
People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance.
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
April 10, 2025 at 7:09 AM
People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance.
#KeystoneSymposium #HIVcure2025
#KeystoneSymposium #HIVcure2025
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
April 10, 2025 at 6:58 AM
Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa.
#KeystoneSymposium #HIVcure
#KeystoneSymposium #HIVcure
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
March 13, 2025 at 12:16 PM
RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.
This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.
March 11, 2025 at 7:21 PM
This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.
The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.
March 11, 2025 at 7:21 PM
The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.
Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.
March 11, 2025 at 7:21 PM
Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
March 11, 2025 at 1:37 PM
RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.
Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.